Zacks Investment Research Downgrades Nu Skin Enterprises (NUS) to Hold
Zacks Investment Research lowered shares of Nu Skin Enterprises (NYSE:NUS) from a buy rating to a hold rating in a report issued on Wednesday.
According to Zacks, “Nu Skin is a premier anti-aging company. The company’s anti-aging products feature the ageLOC line of products including ageLOC Tru Face Essence Ultra firming serum, the ageLOC TR90 weight management and body shaping system, ageLOC R2 nutritional supplement, and ageLOC Transformation daily skin care system. “
Other equities research analysts have also recently issued reports about the stock. Deutsche Bank raised their price target on shares of Nu Skin Enterprises from $75.00 to $77.00 and gave the stock a buy rating in a research note on Friday, February 16th. Pivotal Research reissued a buy rating and issued a $90.00 target price on shares of Nu Skin Enterprises in a research report on Friday, February 16th. ValuEngine raised shares of Nu Skin Enterprises from a hold rating to a buy rating in a research report on Friday, February 2nd. Citigroup reissued a buy rating and issued a $81.00 target price (up from $70.00) on shares of Nu Skin Enterprises in a research report on Tuesday, January 23rd. Finally, Stifel Nicolaus raised their target price on shares of Nu Skin Enterprises from $50.00 to $57.00 and gave the stock a sell rating in a research report on Friday, February 16th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. The company has an average rating of Hold and a consensus price target of $71.29.
Nu Skin Enterprises (NYSE:NUS) last released its quarterly earnings results on Thursday, February 15th. The company reported $1.20 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.19 by $0.01. Nu Skin Enterprises had a net margin of 5.68% and a return on equity of 25.23%. The company had revenue of $666.20 million for the quarter, compared to analysts’ expectations of $667.39 million. During the same period last year, the company earned $0.79 EPS. The firm’s revenue for the quarter was up 25.4% compared to the same quarter last year. sell-side analysts predict that Nu Skin Enterprises will post 3.56 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Wednesday, March 14th. Investors of record on Monday, February 26th will be given a $0.365 dividend. The ex-dividend date is Friday, February 23rd. This is a boost from Nu Skin Enterprises’s previous quarterly dividend of $0.36. This represents a $1.46 annualized dividend and a dividend yield of 2.02%. Nu Skin Enterprises’s dividend payout ratio (DPR) is currently 61.60%.
In related news, Chairman Steven Lund sold 13,978 shares of the firm’s stock in a transaction that occurred on Friday, January 19th. The shares were sold at an average price of $70.01, for a total value of $978,599.78. Following the sale, the chairman now directly owns 4,769 shares of the company’s stock, valued at $333,877.69. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 195,978 shares of company stock worth $13,512,733 over the last three months. Corporate insiders own 5.20% of the company’s stock.
Hedge funds have recently made changes to their positions in the business. Wolverine Asset Management LLC lifted its position in Nu Skin Enterprises by 106.9% during the fourth quarter. Wolverine Asset Management LLC now owns 1,514 shares of the company’s stock valued at $103,000 after buying an additional 23,378 shares in the last quarter. Cerebellum GP LLC acquired a new position in Nu Skin Enterprises during the fourth quarter valued at approximately $124,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in Nu Skin Enterprises during the third quarter valued at approximately $148,000. Amundi Pioneer Asset Management Inc. acquired a new position in Nu Skin Enterprises during the fourth quarter valued at approximately $192,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Nu Skin Enterprises by 38.6% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,082 shares of the company’s stock valued at $210,000 after buying an additional 858 shares in the last quarter. 76.17% of the stock is currently owned by hedge funds and other institutional investors.
About Nu Skin Enterprises
Nu Skin Enterprises, Inc is a direct selling company that develops and distributes personal care products and nutritional supplements, and a range of other products and services. The Company offers anti-aging personal care products and nutritional supplements under its Nu Skin and Pharmanex brands. The Nu Skin brand offers a range of products, including ageLOC Me customized skin care system, ageLOC Spa systems and ageLOC Transformation anti-aging skin care system.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nu Skin Enterprises Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nu Skin Enterprises and related companies with MarketBeat.com's FREE daily email newsletter.